Abstract：[Abstract] Objective To explore effect of Tiotropium Bromide combined with Salmeterol/Fluticasone Propionate treatment on lung function of COPD patients. Methods clinical data of 75 cases of COPD patients in the Central Hospital of Fushun City from January 2013 to January 2015 were analyzed, According to different treatment method, they were divided into two groups, general treatment group (Spasmolysis and asthma foundation treatment) 35 cases and combined treatment group (Tiotropium Bromide unite Salmeterol/Fluticasone Propionate treatment) 40 cases. The clinical symptom scores, lung function, total effective rate of clinical treatment of two groups of patients before treatment and after treatment were detected. The lung function was tested by lung function instrument. Results There was no statiscal difference of clinical symptom scores [(6.60±2.21) vs (7.14±2.32) scores] between two groups of COPD patients before treatment (t=1.03, P ＞ 0.05). There was no statiscal difference of FEV1 [(1.12±0.67) vs (1.13±0.58) L], FEV1/FVC% [(52.28±3.29)% vs （52.48±3.64）% L], FEV1%Pred [(52.34±4.03)% vs (53.16±3.92)%] between two groups of COPD patients before treatment (t=0.07, 0.25, 0.89, P > 0.05). The clinical symptom score [(4.23±1.62)scores] of combined treatment group COPD patients after treatment was better than general treatment group [(5.66±1.45)scores, t=4.00, P < 0.05]. The FEV1 [(1.96±0.55)L], FEV1/FVC% [(59.92±3.47)%], FEV1%Pred [(63.12±5.24)%] of combined treatment group after treatment were better than general treatment group [(1.54±0.48)L, (56.20±3.24)%, (56.72±4.87)%] (t=3.50, 4.78, 5.45, P < 0.05), the clinical effective rate (100.0%) of combined treatment group COPD patients was higher than general treatment group (74.3%), the difference were statistically significant (χ2=29.49, P < 0.05). Conclusion The clinical effacy of tiotropium bromide combined with salmeterol/ fluticasone propionate treatment on COPD patients is obvious, has good prognosis, which is worthy of clinical application.
许迎辉 李 响 韩玉英. 噻托溴铵联合沙美特罗/丙酸氟替卡松吸入治疗对慢性阻塞性肺疾病患者肺功能的影响[J]. 中国医药导报, 2016, 13(3): 146-149.
XU Yinghui LI Xiang HAN Yuying. Effect of Tiotropium Bromide combined with Salmeterol/Fluticasone Propionate treatment on lung function of COPD patients. 中国医药导报, 2016, 13(3): 146-149.
[参考文献]
[1] Ｒabe KF，Hurd S，Anzueto A，et al． Global strategy for the diagnosis，management，and prevention of chronic obstructive pulmonary disease：GOLD executive summary [J]. Am JＲespir Crit Care Med，2007，176（6）：532-555．
[2] Currie GP，Ｒossiter C，Miles SA，et al． Effects of tiotropium and other long acting bronchodilators in chronic obstructive pulmonary disease [J]. Pulm Pharmacol Ther，2006， 19（2）：1112-1119．
[3] 中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南（2013年修订版）[J].中华结核和呼吸杂志，2013，36（4）：255.
[4] Sozanska E，Barczyk A，Biedron-Machura M，et al． Usefulness of induced sputum in the diagnostics of selected chronic inflammatory airway diseases [J]. Pneumonol Alergol Pol，2009，77（4）：349-356．
[5] Profita M，Giorgi ＲD，Sala A，et al． Muscarinic receptors，leukotriene B4 production and neutrophilic inflammation in COPD patients [J]. Allergy，2005，60（11）：1361-1369．
[6] Ohta S，Oda N，Yokoe T，et al. Bsect of tiotropium bromide onairway in flammation and remodelling in a mouse model of asthma [J]. Clin Exp Allergy，2010，40（8）：1266-1275.
[7] Chang CL，Mills GD，Mckchian JD，et al. Cardio-selective and non-selective beta-blokers in chronic obstructive pulmonary disease：effects on bronchodilator response and exercise [J]. In Med J，2010，40（3）：193-200.
[8] Ageev FT，Makarova GV，Patrusheva IF.et al. The efficacy and safety of the combination of B-blocker bisoprolol and if inhibitor ivabradine in patients with stable angina and chronic obstructive pulmonary disease [J]. Kardiologiia，2010，50（10）：22-26.
[9] Brashier B. Tiotropim administered by apressrized metered dose inhaler （pMDI） and spacer prodces a similar bronchodilator response as that administered by a rota-haler in adlt sbjects with stable moderate- to-severe COPD [J]. RespirMed，2008，102（4）：628.
[10] 叶青，张立波，范荣梅，等.布地奈德福莫特罗联合噻托溴铵对重度慢性阻塞性肺疾病稳定期患者的疗效分析[J].中华肺部疾病杂志，2014，7（3）：45-48.
[11] Troosters T，Celli B，Lystig T，et al． Tiotropium as a first Maintenance drug in COPD： secondary analysis of the UPLIFT trial [J]. Eur Ｒespir J，2010，3（1）：65-73．
[12] 李光才，何媛.噻托溴铵联合沙美特罗丙酸氟替卡松治疗稳定期COPD的临床效果[J].临床肺科杂志，2015， 20（1）：80-83.
[13] 贾嵘，刘磊，白巧红.噻托溴铵联合沙美特罗丙酸氟替卡松治疗对COPD患者肺功能及CRP的影响[J].内科，2014，9（4）：386-388.
[14] 张帆.噻托溴铵联合沙美特罗替卡松治疗慢性阻塞性肺疾病68例疗效观察[J].中国医药导报，2009，6（15）：68-69.
[15] 祖丽梅.噻托溴铵联合沙美特罗替卡松雾化吸入在COPD治疗中的效果观察[J].中国继续医学教育，2015， 7（18）：185-186.
[16] 龙瑜琴，程晓明.唆托澳铰联合大剂量舒利迭治疗重度支气管哮喘合并慢性阻塞性肺疾病的效果观察[J].中国医药导报，2013，10（2）：166-168．
[17] 迟玉敏，金梅，杜俊凤，等.噻托溴铵联合沙美特罗替卡松吸入对稳定期COPD患者血清炎症细胞因子及肺功能的影响评价[J].临床肺科杂志，2013，18（12）：2294-2295.
[18] 滕鸿，李岱.噻托溴铵联合沙美特罗/丙酸氟替卡松吸入治疗对COPD患者肺功能的影响[J].浙江实用医学，2015，20（3）：185-187.
[19] 仝惠民，蒋萍.噻托溴铵联合沙美特罗/丙酸氟替卡松对慢性阻塞性肺疾病稳定期患者的疗效[J].中国慢性病预防与控制，2012，20（6）：663-665.
[20] 朱晓梅，聂秀红，杨晶晶.慢性阻塞性肺疾病患者合并骨质疏松对预后的影响[J].中国现代医生，2015,53（30）：24-27.
[21] 褚岩.雾化吸入、药物及康复训练联合治疗慢性阻塞性肺疾病的疗效观察[J].中国现代医生，2015,53（28）：77-79.
[22] 马萍，朱聪，陈敏.综合性护理干预对慢性阻塞性肺疾病患者治疗依从性及复发的影响[J].中国现代医生，2015， 53（22）：133-136.
[23] 朱秋蕾.噻托溴铵与沙美特罗/氟替卡松联合治疗慢性阻塞性肺疾病的临床疗效分析[J].中国现代医生，2015， 53（7）：20-21.
[24] 孙林，周红兵，艾伟，等.呼吸训练联合沙美特罗卡松和噻托溴铵在老年COPD患者中的应用研究[J].检验医学与临床，2014，11（6）：765-767.
京公网安备 11010502046598号